(Q43978367)

English

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

scientific article published in January 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

1 reference

based on heuristic

1 reference

based on heuristic

author name string

S Fetscher

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

W Brugger

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

R Engelhardt

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

L Kanz

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

J Hasse

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

H Frommhold

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

M Wenger

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

W Lange

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

R Mertelsmann

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

publication date

1 January 1997

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

49-56

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurological and cognitive impairment in long-term survivors of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive combined modality therapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Dealing with initial chemotherapy doses: a new basis for treatment optimisation in limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene therapy for lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum p53 antibodies as early markers of lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical resection in the management of small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

The surgery of lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost of success in the treatment of thoracic malignancies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of operation without adjuvant therapy in the treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008232329498

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008232329498

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43978367&oldid=2160487707"